PRODUCT INFORMATION

MN-001
Item No. 11948

CAS Registry No.: 125961-82-2
Formal Name: 4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]-butanoic acid
Synonyms: KCA 757, Tipelukast
MF: C_{29}H_{38}O_{7}S
FW: 530.7
Purity: ≥98%
UV/Vis.: λ_{max}^\text{abs}: 216, 252, 311 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MN-001 is supplied as a solid. A stock solution may be made by dissolving the MN-001 in the solvent of choice. MN-001 is soluble in the organic solvent ethanol, which should be purged with an inert gas. The solubility of MN-001 in ethanol is approximately 1 mg/ml. MN-001 is also sparingly soluble in the organic solvents chloroform and ethyl acetate.

Description

MN-001 is an orally bioavailable anti-inflammatory agent whose mechanisms of action include inhibition of eosinophil migration, antagonism of leukotriene receptors, and inhibition of phosphodiesterases 3 and 4.\(^1\) Other mechanisms of action described for MN-001 include the inhibition of 5-lipoxygenase, phospholipase C, and thromboxane A\(_2\).\(^\text{1,2}\) MN-001 is reported to produce antifibrotic and anti-inflammatory activity in multiple preclinical models and is undergoing clinical investigations for use in the treatment of patients with either idiopathic pulmonary fibrosis or non-alcoholic steatohepatitis.\(^\text{1,2}\)

References